Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

Yoshikawa, Katsuhiro; Ishida, Mitsuaki; Yanai, Hirotsugu; Tsuta, Koji; Sekimoto, Mitsugu; Sugie, Tomoharu

doi:10.1371/journal.pone.0253176

Cited by 13 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These articles contained 26 studies that involved 4325 cancer patients. The tumor types explored in these 26 studies included soft tissue sarcoma [ 26 ], hepatocellular carcinoma [ 27 – 30 ], acute myeloid leukemia [ 31 ], pancreatic cancer [ 32 ], cholangiocarcinoma [ 33 ], bladder cancer [ 34 ], lung cancer [ 35 – 38 ], esophageal cancer [ 39 , 40 ], breast cancer [ 41 – 44 ], head and neck squamous cell carcinoma [ 45 , 46 ], gastric cancer [ 47 ], gallbladder cancer [ 48 ], cervical adenocarcinoma [ 49 ], and colorectal cancer [ 50 ]. The study samples ranged from 43 to 444.…”

Section: Resultsmentioning

confidence: 99%

“…B. (2020) [ 47 ] China 2010–2014 More than 5 years 444 Gastric cancer IHC Tissue ≥ 4 a Univariate analysis 1.55 (1.19–2.01) 7 Albrecht T. (2021) [ 48 ] Germany 1995–2016 NS 95 Gallbladder cancer IHC Tissue Optimal cutoff Univariate analysis 2.72 (1.35–5.47) 6 Murakami T. (2021) [ 49 ] Japan 2004–2014 NS 67 Cervical adenocarcinoma IHC Tissue ≥ ++ a Univariate analysis 6.39 (2.04–19.98) 7 Yoshikawa K. (2021) [ 44 ] Japan 2006–2018 NS 61 Breast cancer IHC Tissue ≥ 50 a Univariate analysis 2.99 (0.6–15.01) 6 Zhao K. (2021) [ 51 ] China 2006–2018 Until 2019 114 Esophageal cancer IHC Tissue ≥ 2 a Univariate/multivariate analysis 1.646 (1.006–2.691) 7 Lee J. B.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Zhang

Liu²,

Zheng

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded conflicting results. Thus, the present study aimed to evaluate overall prognostic value of CD155 in cancer patients, using a comprehensive analysis. Methods Online databases were searched, data was collected, and clinical value of CD155 was evaluated by combining hazard ratios (HRs) or odds ratios (ORs). Results The present study involved meta-analysis of 26 previous studies that involved 4325 cancer patients. These studies were obtained from 25 research articles. The results of the study revealed that increased CD155 expression was significantly associated with reduced OS in patients with cancer as compared to low CD155 expression (pooled HR = 1.772, 95% CI = 1.441–2.178, P < 0.001). Furthermore, subgroup analysis demonstrated that the level of CD155 expression was significantly associated with OS in patients with digestive system cancer (pooled HR = 1.570, 95% CI = 1.120–2.201, P = 0.009), hepatobiliary pancreatic cancer (pooled HR = 1.677, 95% CI = 1.037–2.712, P = 0.035), digestive tract cancer (pooled HR = 1.512, 95% CI = 1.016–2.250, P = 0.042), breast cancer (pooled HR = 2.137, 95% CI = 1.448–3.154, P < 0.001), lung cancer (pooled HR = 1.706, 95% CI = 1.193–2.440, P = 0.003), head and neck cancer (pooled HR = 1.470, 95% CI = 1.160–1.862, P = 0.001). Additionally, a significant correlation was observed between enhanced CD155 expression and advanced tumor stage (pooled OR = 1.697, 95% CI = 1.217–2.366, P = 0.002), LN metastasis (pooled OR = 1.953, 95% CI = 1.253–3.046, P = 0.003), and distant metastasis (pooled OR = 2.253, 95% CI = 1.235–4.110, P = 0.008). Conclusion Altogether, the results of the present study revealed that CD155 acted as an independent marker of prognosis in cancer patients, and it could provide a new and strong direction for cancer treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Zhang

Liu²,

Zheng

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…In total, 62 patients with TNBC were included in the study cohort. This study cohort was fundamentally the same as that used in our previous studies [27][28][29]. In a previous study, we analyzed the relationship between adipophilin expression, a lipid droplet-associated protein, and the clinicopathological features of patients with TNBC [27].…”

Section: Patient Selectionmentioning

confidence: 99%

“…In a previous study, we analyzed the relationship between adipophilin expression, a lipid droplet-associated protein, and the clinicopathological features of patients with TNBC [27]. In our previous studies, we examined the significance of PD-L1 expression in cancer-associated fibroblasts [28], and the relationship between CD155, an immune checkpoint protein, and PD-L1 expression [29] in TNBC tissues. Thus, the contents of the present study do not overlap with those of our previous studies [27][28][29].…”

Section: Patient Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy is a critical issue. Several assays have been used to evaluate PD-L1 expression, and a few studies comparing PD-L1 expression using various primary antibodies in TNBC tissues have been reported. However, the expression profiles of the PD-L1 using the 73–10 assay have not yet been analyzed in TNBC tissues. Methods We analyzed the PD-L1 immunohistochemical profiles of 62 women with TNBC using the 73–10, SP142 (companion diagnostic for atezolizumab), and E1L3N assays. PD-L1 expression on immune cells (ICs) and tumor cells (TCs) was also evaluated, and PD-L1 positivity was defined as a PD-L1-expressing ICs or TCs ≥ 1%. Results The expression rates of PD-L1 were 79.0%, 67.7%, and 46.8% on ICs, and 17.7%, 6.5%, and 12.9% on TCs using the 73–10, SP142, and E1L3N assays, respectively. The concordance rates between the 73–10 and SP142 assays were 85.5% (on ICs) and 88.7% (on TCs), respectively, and substantial agreement on ICs (coefficient 0.634) and moderate agreement (coefficient 0.485) on TCs were noted. Sample age and tumor diameter did not influence the ratio of PD-L1 expression among the assays. Conclusions The positive rate on ICs and TCs of the 73–10 assay was higher than that of the SP 142 and E1L3N assays. Although substantial agreement on ICs and moderate agreement on TCs between the 73–10 and SP142 assays was noted in the present cohort, further studies are needed to clarify the PD-L1 expression status using various primary antibodies in a larger patient population. This would lead to the establishment of an effective evaluation method to assess the predictive value of anti-PD-L1 immunotherapy.

show abstract

CD155 as an emerging target in tumor immunotherapy

Wu,

Liu,

Dai

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

Cited by 13 publications

References 31 publications

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

CD155 as an emerging target in tumor immunotherapy

Contact Info

Product

Resources

About